HomeCompareSBHMY vs FCPT

SBHMY vs FCPT: Dividend Comparison 2026

SBHMY yields 1.45% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FCPT wins by $19.1K in total portfolio value
10 years
SBHMY
SBHMY
● Live price
1.45%
Share price
$15.89
Annual div
$0.23
5Y div CAGR
27.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.0K
Annual income
$2,333.46
Full SBHMY calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — SBHMY vs FCPT

📍 FCPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSBHMYFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SBHMY + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SBHMY pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SBHMY
Annual income on $10K today (after 15% tax)
$123.31/yr
After 10yr DRIP, annual income (after tax)
$1,983.44/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, FCPT beats the other by $2,925.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SBHMY + FCPT for your $10,000?

SBHMY: 50%FCPT: 50%
100% FCPT50/50100% SBHMY
Portfolio after 10yr
$39.5K
Annual income
$4,054.37/yr
Blended yield
10.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

SBHMY
No analyst data
Altman Z
2.8
Piotroski
6/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SBHMY buys
0
FCPT buys
0
No recent congressional trades found for SBHMY or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSBHMYFCPT
Forward yield1.45%6.05%
Annual dividend / share$0.23$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR27.6%15.8%
Portfolio after 10y$30.0K$49.1K
Annual income after 10y$2,333.46$5,775.28
Total dividends collected$8.6K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SBHMY vs FCPT ($10,000, DRIP)

YearSBHMY PortfolioSBHMY Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$10,885$185.10$11,401$700.92$516.00FCPT
2$11,887$240.28$13,064$864.84$1.2KFCPT
3$13,032$312.92$15,051$1,072.48$2.0KFCPT
4$14,354$409.11$17,442$1,337.22$3.1KFCPT
5$15,896$537.34$20,340$1,677.08$4.4KFCPT
6$17,718$709.63$23,880$2,116.57$6.2KFCPT
7$19,902$943.27$28,241$2,689.36$8.3KFCPT
8$22,558$1,263.50$33,660$3,442.07$11.1KFCPT
9$25,845$1,707.89$40,456$4,439.95$14.6KFCPT
10$29,988$2,333.46$49,063$5,775.28$19.1KFCPT

SBHMY vs FCPT: Complete Analysis 2026

SBHMYStock

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Full SBHMY Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this SBHMY vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SBHMY vs SCHDSBHMY vs JEPISBHMY vs OSBHMY vs KOSBHMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.